|
|
CeraPedics,
Inc. is developing and commercializing products for the
orthopedic bone substitutes market. The Company’s products
utilize a proprietary small peptide called P-15™. This
peptide has been identified to play an active role in
initiating the formation of bone. CeraPedics’ products
should provide a safe, efficacious, and economical
alternative to autograft and recombinant bone growth factor
products for most procedures requiring a bone graft
including spine fusion, trauma, and joint reconstruction.
CeraPedics’ first product, P-15 Putty, is currently under an
Investigational Device Exemption (IDE) clinical
investigation for FDA regulatory approval.
|
|
|
